Inhibiting Glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

Blood

Volumn 122, Issue 20, 2013, Pages 3521-3532

  Willems, Lise ^a,b,c   Jacque, Nathalie ^b   Jacquel, Arnaud ^d   Neveux, Nathalie ^a   Maciel, Thiago Trovati ^e   Lambert, Mireille ^b   Schmitt, Alain ^f   Poulain, Laury ^b   Green, Alexa S ^b   Uzunov, Madalina ^a   Kosmider, Olivier ^b,c,h   Radford Weiss, Isabelle ^g   Moura, Ivan Cruz ^e   Auberger, Patrick ^d   Ifrah, Norbert ^h   Bardet, Valerie ^a,b,c   Chapuis, Nicolas ^a,b,c   Lacombe, Catherine ^a,b,c   Mayeux, Patrick ^b,c   Tamburini, Jerome ^a,b,c   Bouscary, Didier ^a,b,c   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

^e INSERM   (France)

^f INSTITUT COCHIN   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GLUTAMATE AMMONIA LIGASE; GLUTAMINASE; GLUTAMINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ION EXCHANGE CHROMATOGRAPHY; LEUKEMIA CELL; MOUSE; NONHUMAN; PECTOBACTERIUM CHRYSANTHEMI; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TARGETING; WESTERN BLOTTING;

EID: 84888271341     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-493163     Document Type: Article

References (49)

1. Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001;15(21):2852-2864.
2. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 2008;111(1):379-382.
3. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Récher C. A critical role for Lyn in acute myeloid leukemia. Blood. 2008;111(4):2269-2279.
4. Hoshii T, Tadokoro Y, Naka K, et al. mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest. 2012;122(6):2114- 2129.
5. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood. 2005;106(13):4261-4268.
6. Tamburini J, Green AS, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 2009;114(8):1618-1627.
7. Willems L, Chapuis N, Puissant A, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia. 2012;26(6):1195-1202.
8. Chapuis N, Tamburini J, Green AS, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010;16(22):5424-5435.
9. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293.
10. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 1998;273(23):14484-14494.
11. Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab. 2009;296(4):E592-E602.
12. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan K-L. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol. 2008;10(8):935-945.
13. Sancak Y, Peterson TR, Shaul YD, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 2008;320(5882):1496-1501.
14. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15(4):254-266.
15. Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521-534.
16. Wiederschain D, Wee S, Chen L, et al. Singlevector inducible lentiviral RNAi system for oncology target validation. Cell Cycle. 2009;8(3):498-504.
17. Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010;207(4):731-750.
18. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell. 2010;141(2):290-303.
19. Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle. 2010;9(17):3470-3478.
20. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330(6009):1340-1344.
21. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297-308.
22. Vander Heiden MG, Locasale JW, Swanson KD, et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 2010;329(5998):1492-1499.
23. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427-433.
24. Ochiai H, Higa K, Hishiyama N, Hisamatsu S, Fujise H. Characterization of several amino acid transports and glutamine metabolism in MOLT4 human T4 leukemia cells. Clin Lab Haematol. 2006;28(6):399-404.
25. Evans K, Nasim Z, Brown J, et al. Acidosissensing glutamine pump SNAT2 determines amino acid levels and mammalian target of rapamycin signalling to protein synthesis in L6 muscle cells. J Am Soc Nephrol. 2007;18(5):1426-1436.
26. Pinilla J, Aledo JC, Cwiklinski E, Hyde R, Taylor PM, Hundal HS. SNAT2 transceptor signalling via mTOR: a role in cell growth and proliferation? Front Biosci (Elite Ed). 2011;3:1289-1299.
27. Capizzi RL, Bertino JR, Skeel RT, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med. 1971;74(6):893-901.
28. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E III, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43(11):5601-5607.
29. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178.
30. Miller HK, Salser JS, Balis ME. Amino acid levels following L-asparagine amidohydrolase (EC. 3.5.1.1) therapy. Cancer Res. 1969;29(1):183-187.
31. Müller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28(2):97-113.
32. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99(6):1986-1994.
33. Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models. Anticancer Res. 2007;27(4 C):2561-2572.
34. Iiboshi Y, Papst PJ, Hunger SP, Terada N. L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun. 1999;260(2):534-539.
35. Reinert RB, Oberle LM, Wek SA, et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006;281(42):31222-31233.
36. Clarkson B, Krakoff I, Burchenal J, et al. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer. 1970;25(2):279-305.
37. Ohnuma T, Holland JF, Freeman A, Sinks LF. Biochemical and pharmacological studies with asparaginase in man. Cancer Res. 1970;30(9):2297-2305.
38. Capizzi RL, Davis R, Powell B, et al. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 1988;6(3):499-508.
39. Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit: multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia. 2005;19(12):2082-2089.
40. Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood. 2000;96(8):2879-2886.
41. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y, Ohzeki T. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia. 2001;15(12):1892-1897.
42. Okada S, Hongo T, Yamada S, et al. In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia. Br J Haematol. 2003;123(5):802-809.
43. Hutson RG, Kitoh T, Moraga Amador DA, Cosic S, Schuster SM, Kilberg MS. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol. 1997;272(5 Pt 1):C1691-C1699.
44. Appel IM, den Boer ML, Meijerink JPP, Veerman AJ, Reniers NC, Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood. 2006;107(11):4244-4249.
45. Aslanian AM, Kilberg MS. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells. Biochem J. 2001;358(Pt 1):59-67.
46. Rotoli BM, Uggeri J, Dall'Asta V, et al. Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem. 2005;15(6):281-292.
47. Tardito S, Chiu M, Uggeri J, et al. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of b-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets. 2011;11(8):929-943.
48. Lamoureux F, Thomas C, Crafter C, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 2013;19(4):833-844.
49. Han W, Sun J, Feng L, et al. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS ONE. 2011;6(12):e28491.